Taipei, February 15, 2016 – Polaris Group announced today that its shares have been listed for trading on the Emerging Stock Board (ESB) of the Taipei Exchange (TPEx). Shares of Polaris Group are traded under stock code 6550. CTBC Bank is acting as transfer agent for shares of Polaris Group. No new shares were issued by Polaris Group in connection with the listing.
Listing on TPEx will allow Polaris Group expanded access to international capital markets and facilitate public trading of Polaris Group shares on the ESB. Information about Polaris Group’s shares traded on the ESB can be found at
About ADI‑PEG 20
ADI‑PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI‑PEG 20 is designed to deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency.
About Polaris Group
Polaris Group is a privately held biopharmaceutical company that specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. The company’s lead therapeutic, ADI‑PEG 20, is currently being evaluated in a pivotal Phase 3 trial for hepatocellular carcinoma. Polaris Group is also investigating ADI‑PEG 20 as a treatment for other cancers, such as leukemia, lymphoma, melanoma, mesothelioma, non-small cell lung carcinoma, sarcoma, breast, ovarian, and pancreatic cancer. In addition to the ADI‑PEG 20 program, Polaris Group is researching and developing other biotherapeutic agents and is advancing a small molecule drug program that utilizes a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.
For additional information please visit www.polarispharma.com